Key Takeaways
- • QHP Capital manages $4.5 billion in assets under management and successfully closed its NovaQuest Private Equity Fund II at $500 million in 2022, exceeding its $425 million target, demonstrating strong institutional confidence in its differentiated strategy.
- • The firm targets midsize, founder-led companies in pharmaceutical services that have not yet reached full potential, focusing on building management teams, processes, and systems rather than pursuing aggressive cost-cutting typical of traditional private equity.
- • QHP executes its investment strategy within a 36-month window while maintaining longer-term hold periods of five to seven years, balancing rapid operational transformation with sustained value creation rather than quick exits.
- • The firm has successfully exited two companies from its portfolio of 11 current holdings, validating its thesis that long-term operational improvements in life sciences businesses can generate superior returns compared to financial engineering approaches.
- • QHP traces its heritage to Quintiles (now IQVIA), spinning out from NovaQuest Capital Management in 2022 to establish an independent private equity platform focused exclusively on the life sciences sector.
Summary
QHP Capital has established itself as a contrarian player in private equity by rejecting the traditional playbook of cost-cutting and rapid asset sales in favor of a sustained operational improvement model tailored to life sciences investing. The Raleigh-based firm, which rebranded from NovaQuest Private Equity in 2022, manages $4.5 billion in assets under management and successfully closed its second flagship fund at $500 million in 2022, exceeding its $425 million fundraising target.
The firm's differentiated approach centers on identifying midsize, founder-led companies in pharmaceutical services that possess unrealized potential. Rather than immediately restructuring for margin expansion and buyer appeal, QHP partners with existing management teams to build sustainable competitive advantages through enhanced operational infrastructure, process improvements, and team development. According to Vern Davenport, a partner at QHP and former Triangle healthcare CEO, the firm executes its full investment strategy within a compressed 36-month window, enabling rapid transformation while maintaining longer-term hold periods of five to seven years—a timeline that allows value creation from operational improvements rather than financial arbitrage alone.
QHP's origins trace to Quintiles, a North Carolina-founded contract research organization that evolved into IQVIA. The firm's investment arm, NovaQuest Capital Management, initially focused on venture and growth equity before adding private equity capabilities in 2015. The 2022 spin-out and rebranding to QHP Healthcare Partners (the Q honoring both Quintiles and NovaQuest heritage) formalized the firm's commitment to life sciences-focused private equity as a standalone strategy.
Early evidence supports QHP's thesis. The firm currently manages 11 portfolio companies and has achieved two successful exits, demonstrating that its long-term operational focus can generate returns competitive with more traditional private equity models. This track record suggests that in fragmented pharmaceutical services markets, patient capital combined with genuine operational expertise may outperform the leveraged buyout model that dominates mainstream private equity.
The firm's differentiated approach centers on identifying midsize, founder-led companies in pharmaceutical services that possess unrealized potential. Rather than immediately restructuring for margin expansion and buyer appeal, QHP partners with existing management teams to build sustainable competitive advantages through enhanced operational infrastructure, process improvements, and team development. According to Vern Davenport, a partner at QHP and former Triangle healthcare CEO, the firm executes its full investment strategy within a compressed 36-month window, enabling rapid transformation while maintaining longer-term hold periods of five to seven years—a timeline that allows value creation from operational improvements rather than financial arbitrage alone.
QHP's origins trace to Quintiles, a North Carolina-founded contract research organization that evolved into IQVIA. The firm's investment arm, NovaQuest Capital Management, initially focused on venture and growth equity before adding private equity capabilities in 2015. The 2022 spin-out and rebranding to QHP Healthcare Partners (the Q honoring both Quintiles and NovaQuest heritage) formalized the firm's commitment to life sciences-focused private equity as a standalone strategy.
Early evidence supports QHP's thesis. The firm currently manages 11 portfolio companies and has achieved two successful exits, demonstrating that its long-term operational focus can generate returns competitive with more traditional private equity models. This track record suggests that in fragmented pharmaceutical services markets, patient capital combined with genuine operational expertise may outperform the leveraged buyout model that dominates mainstream private equity.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.